CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 29 enrolled
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03341936
NCT03341936Phase 2Active
CompareCT.gov

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck

Dana-Farber Cancer Institute·interventional·Posted Nov 14, 2017·Updated Jun 18, 2025

In Brief

A Phase 2 clinical trial evaluating Nivolumab and Lirilumab for Squamous Cell Carcinoma of the Head and Neck. Active but no longer recruiting, targeting 29 participants across 1 site.

Detailed Summary

This research study is studying a combination of two immunotherapy drugs, as a possible treatment for locoregionally recurrent squamous cell carcinoma of the head and neck. The immunotherapy drugs involved in this study are: * Nivolumab (Opdivo™) * Lirilumab

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Carcinoma of the Head and Neck
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2Active
201820192020202120222023202420252026
First PostedNov 14, 2017
Enrollment StartMar 15, 2018
Primary CompletionJul 6, 2021
Study CompletionJul 6, 2026
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 8.6 years ago

Interventions

Nivolumabdrug

Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells

Lirilumabdrug

Lirilumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells